Hereditary hearing loss affects millions globally, with mutations in the SLC26A4 gene among the most common genetic triggers, particularly across Asian populations. This condition leads to severe-to-profound deafness accompanied by inner ear malformations, such as an abnormally enlarged vestibular aqueduct and endolymphatic sac.

While gene replacement therapies have long held immense potential, experimental interventions have historically been restricted to the embryonic stage. Delivering genetic material before birth presents steep ethical and practical hurdles, creating a critical roadblock for real-world medical applications.

A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA vaccines generate immunity, revealing that certain non-immune cells help determine vaccine effectiveness.

The study, published in Nature Biotechnology, also introduces a powerful and versatile technology to control the expression of mRNA drugs, which the researchers demonstrate can enhance the effectiveness of mRNA cancer vaccines in preclinical studies of lymphoma. The paper is titled “mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.”

The findings provide a new framework for designing mRNA vaccines and mRNA therapeutics, with immediate implications for cancer immunotherapy, infectious disease vaccines, and gene-editing treatments.

Researchers from the University of Osaka have demonstrated that mitochondrial hyperfusion, when induced by low levels of DRP1 or cellular stress, activates an immune response through the RIG-I–MAVS pathway. Dependent on the involvement of the BAX protein, the release of mitochondrial RNA into the cytosol enhanced natural killer cell cytotoxicity and reduced tumor growth in a xenograft model. The findings, published in Cell Reports, provide new possibilities for cancer research and treatment.

Mitochondria are constantly dividing and fusing within our cells, reshaping themselves to keep up with the cell’s changing needs. Sometimes, though, things go awry, and mitochondria can grow abnormally long. Are these long mitochondria harmful, or might they serve a purpose?

Mitochondria also act as signaling centers, helping the cell sense and respond to trouble. When mitochondria are hyperfused, for example in the stressed, abnormally long state described above, they release their genetic material into the cytosol, where the cell treats it as a warning sign in the same way it would treat a virus.

Researchers from The Hospital for Sick Children (SickKids) in Toronto have found a previously unknown genetic cause of Crohn’s disease and uncovered how those changes trigger inflammation through a key immune pathway. The findings, published in Gastroenterology and involving teams from eight countries, will guide more precise treatments and improve the ability to match patients to therapies based on their unique biology.

“We’ve brought together genetics, RNA sequencing, proteomics and more to try for the first time to map the complete disease pathway, and it’s turned into a remarkable precision medicine story,” says lead author Dr. Aleixo Muise, senior scientist in the Cell & Systems Biology program, staff gastroenterologist and co-director of the Inflammatory Bowel Disease (IBD) Centre at SickKids.

“In our SickKids clinic, we want to find the right drug for each person based on their body’s unique signature. That’s why this paper is so exciting: We have pinpointed a druggable pathway.”